Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annu...(d by low levels or absence of a protein ...)

Date:7/14/2009

d by low levels or absence of a protein called a clotting factor, essential for blood clotting. This inability to clot results from an error in a person's genetic code, and occurs in approximately 1 in 10,000 male births. It is estimated that over 400,000 people worldwide suffer from hemophilia, of which only 25% currently receive therapy. It is estimated that the market for hemophilia treatment is in excess of seven billion dollars annually. There are two types of hemophilia, hemophilia A and hemophilia B. Hemophilia A is caused by a lack of Factor VIII and hemophilia B is caused by a deficiency of Factor IX.

About Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals was founded in 2004 with the mission to revolutionize treatments for hemophilia. The Company is focused on developing products that have the potential to broaden patient access to therapy, including prophylactic use. Greater access and more frequent prophylactic therapy have been shown to reduce complications of the disease and enhance patients' long-term health and quality of life.

Underlying the Company's programs is a novel, proprietary manufacturing technology that allows a greater yield of high-quality protein. Inspiration is utilizing this technology to develop a portfolio of hemophilia and bleeding disorder products that address a $7 billion market worldwide. Inspiration's lead product candidate IB1001, an intravenous recombinant Factor IX, has completed preclinical testing and is now being evaluated in a Phase 1/2-3 clinical study in the United States and Israel and is poised to enter clinical testing in Europe.

'/>"/>

SOURCE Inspiration Biopharmaceuticals Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT